cardiogenic


Also found in: Medical, Encyclopedia, Wikipedia.
Related to cardiogenic: cardiogenic shock, cardiogenic area, Cardiogenic pulmonary edema

car·di·o·gen·ic

 (kär′dē-ō-jĕn′ĭk, -jē′nĭk)
adj.
1. Having origin in the heart.
2. Resulting from a disease or disorder of the heart.

cardiogenic

(ˌkɑːdɪəʊˈdʒɛnɪk)
adj
originating in the heart, or resulting from a disorder of the heart

car•di•o•gen•ic

(ˌkɑr di əˈdʒɛn ɪk)

adj.
originating in the heart; caused by a disorder of the heart.
[1920–25]
Translations

cardiogenic

adj cardiogénico, cardiógeno
Mentioned in ?
References in periodicals archive ?
A systemic inflammatory response syndrome has been implicated in the pathophysiology of cardiogenic shock.
Both percutaneous coronary interventions and coronary artery bypass grafting are seriously underused in patients with MI complicated by cardiogenic shock, according to a nationwide survey.
Global Markets Direct's, 'Cardiogenic Shock - Pipeline Review, H2 2011', provides an overview of the Cardiogenic Shock therapeutic pipeline.
Intubation is necessary in 7 to 20% of patients with severe acute cardiogenic pulmonary oedema despite optimal treatment.
Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.
MENLO PARK, California, October 13 /PRNewswire/ -- Arginox Pharmaceuticals, an emerging specialty pharmaceutical company today announced that the Committee for Orphan Medical Products (COMP), a division of the European Medicines Agency (EMEA), has recommended orphan drug designation in the European Union to Tilarginine Acetate Injection (TAI) for the treatment of cardiogenic shock (CS).
Patients with either cardiogenic or septic shock were recruited because severe sepsis may coexist with myocardial dysfunction in some patients and some patients with cardiogenic shock may have a significant inflammatory response similar to sepsis.
Arginox Pharmaceuticals, an emerging specialty pharmaceutical company, today announced that it has begun patient enrollment in Europe in TRIUMPH, a pivotal Phase III trial of the company's lead investigational drug, Tilarginine Acetate Injection (TAI), for the treatment of cardiogenic shock (CS), one of the most serious complications of a heart attack.
The data from this analysis supports the recently released new ACCF/AHA/SCAI guidelines which included Impella as a Class I recommendation for cardiogenic shock after STEMI.
The paper, "Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI)," concludes that the "results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail.
Hathaway's cardiovascular clinical and biopharmaceutical experience will be of great value to Arginox as we advance our lead product candidate through a pivotal Phase 3 trial to treat patients with cardiogenic shock, one of the most serious complications of a heart attack," said Kenneth E.